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A  cohort  based  study  has  been  undertaken  to  investigate  the  possible  association  of genetic  polymor-
phisms  in  genes  functionally  related  to follicular  T  helper  (TfH)  cells  with  non-responsiveness  to  hepatitis
B  virus (HBV)  vaccination.  A total  of  24  single  nucleotide  polymorphisms  (SNPs)  in 6 TfH  related  genes
(CXCR5,  ICOS,  CXCL13,  IL-21,  BCL6  and  CD40L)  were  investigated  in  20 non-responders  and  45  responders
to HBV vaccination.  Genetic  association  analysis  revealed  that  three  SNPs  (rs497916,  rs3922,  rs676925)
in  CXCR5  and one  SNP  (rs355687)  in  CXCL13  were  associated  with  hepatitis  B vaccine  efﬁcacy.  In addi-
tion,  signiﬁcantly  unbalanced  distributions  of  two haplotypes,  deﬁned  by  three  SNPs  (rs497916,  rs3922,
rs676925)  within  CXCR5,  were  also  seen  between  non-responders  and  responders.  Furthermore,  we
demonstrated  that  the  rs3922  “GG”  genotype  was  associated  with  higher  levels  of  CXCR5  than  the “AG”XCL13
epatitis B vaccine
on-response
and  “AA”  genotype  in a  group  of  healthy  volunteers.  A  dual  luciferase  report  assay  was  used to  conﬁrm
that  the “G”  allele  in  rs3922  may  lead  to higher  gene  expression  than  the  “A” allele,  implicating  that  rs3922
might  be a functional  SNP  affecting  CXCR5  expression.  These  results  indicated  that  polymorphism  asso-
ciated  changes  in CXCR5  expression  in TfH cells  may  be associated  with  non-responsiveness  to hepatitis
B  vaccination.
ublis© 2014  The  Authors.  P
. Introduction
Hepatitis B vaccines have an outstanding record of safety and
ffectiveness. However, a small minority of vaccinees, so called
on-responders, produce an inadequate neutralizing antibody
esponse following receipt of the standard vaccination regime and
Abbreviations: TfH, follicular T helper cells; UTR, un-translated regions; CXCR5,
hemokine (C-X-C motif) receptor 5; CXCL13, chemokine (C-X-C motif) ligand
3;  BCL6, B-cell CLL/lymphoma 6; IL-21, interleukin 21; ICOS, inducible T-cell co-
timulator; CD40L, CD40 ligand; PBMC, peripheral blood mononuclear cell; MFI,
ean ﬂuorescence intensity.
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are therefore probably still susceptible to infection with hepatitis
B virus (HBV) [1,2]. In addition to a number of technical factors
such as the intervals between the administration of vaccine, doses
administered and speciﬁc vaccine formulation, a number of reports
have suggested that vaccinee speciﬁc variations such as age, male
gender, obesity, smoking, chronic disease, immunodeﬁciency and
crucially genetic predisposition may  also be involved in low or
null responses to HBV vaccines [3–8]. In recent years, an increas-
ing number of reports have linked speciﬁc genetic polymorphisms
of immune system markers such as IL-1, IL-2, IL-4, IL-10, IL-4RA,
IL-13 and TLR-2 with non-responsiveness to HBV vaccine [4,9,10].
It is universally recognized that most vaccines in current use
are able to induce the synthesis of long-lived protective antibod-
ies from memory B cells and plasma cells. Help from speciﬁc CD4+
subsets of T cells to B cells is a prerequisite for this humoral immu-
nity. Follicular T helper (TfH) cells are a newly recognized lineage of
CD4+ T cells [11], that were originally discovered in the B cell folli-
cles of secondary lymphoid organs with the deﬁning feature of high
expression of the chemokine receptor CXCR5. There are accumulat-
ing evidences that these TfH cells are the key T-cell subset required
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or the formation of germinal centers (GCs) and the generation of
ntigen speciﬁc T cell-dependent antibody responses [11–15].
That TfH cells are actively engaged in responses to vaccination
as been shown in a number of different virus systems. Ben-
ebibel et al. reported that peripheral TfH-like cells, marked as
D4+ICOS+CXCR3+CXCR5+, are associated with protective antibody
esponses after seasonal ﬂu vaccination [16]. The efﬁcacy of the
oot and mouth disease vaccine (FMDV) may  also be enhanced
hrough the generation of TfH cells [17,18]. Furthermore, the
on-responsiveness of HIV-infected individuals to the 2009 H1N1
accine has been primarily attributed to the impairment of circu-
ating TfH cells [19]. In the case of HBV, the abnormal expressions
f TfH-related molecules have been reported to be at least par-
ially responsible for the dysfunction of immune responses during
hronic HBV infection [20,21].
Despite this clear evidence that TfH cells have an important role
n the humoral immune response to a number of vaccines, the rela-
ionship between TfH cells and speciﬁc antibody responses to HBV
accine has not as yet received sufﬁcient attention. Given the grow-
ng recognition of the importance of TfH cells in generating a strong
umoral immune response, it seems reasonable to hypothesize that
olymorphisms of TfH related molecules may  be associated with
on-responsiveness to HBV vaccination. Therefore, in this study a
otal of 24 single nucleotide polymorphisms (SNPs) within six genes
CXCR5, ICOS, CXCL13, IL-21, BCL6 and CD40L) were selected and
nalyzed.
. Materials and methods
.1. Study cohort
The cohort recruited for the current study was a subset from
 previous survey on non-responders to HBV vaccine [4,22]. The
etails for screening were described in Supplementary Fig. 1. In
rief, a total of 37,221 ethnic Han Chinese volunteers with no
epatitis B vaccination history were recruited. All recruited vol-
nteers were vaccinated with 10 g of recombinant HBV vaccine
Shenzhen Kangtai Biological Products Co., Ltd., Shenzhen, Guang-
ong) according to the standard 0, 1, and 6 months vaccination
chedule. Anti-HBs titers were tested at 7th month after initiating
he vaccination regime and individuals whose anti-HBs titer was
ower than 10 mIU/ml were re-vaccinated with a further 3 doses
f HBV. Levels of Anti-HBs antibody were re-tested approximately
ne month after the ﬁnal dose of vaccine was administered. For
he present study, volunteers with either evidence of previous HBV
nfection or deemed to be suffering from an occult HBV infection
ere excluded. More screening criteria were listed in Supplemen-
ary Fig. 1. At the end of this process 26 individuals from the cohort
ecruited were deﬁned as authentic non-responders based on pro-
ucing anti-HBs levels of less than 10 mIU/ml after having received
 total of six doses of vaccine administered over two consecutive
ounds of vaccination schedule. DNA samples from 20 of these non-
esponders were available for use in this study. For comparative
urpose, after considering almost the same criteria for screening
on-responders, a group of vaccine responders were identiﬁed on
he basis of having produced anti-HBs levels equal to or more than
00 mIU/ml after having received the standard 3 doses of vaccine.
inally 45 responders were randomly selected and there are no sig-
iﬁcant differences between the responders and non-responders in
ge (age range 25–60 for responders vs. age range 30–59 for non-
esponders, P = 0.0512) and gender (23F/22M for responders vs.
F/13M for non-responders, P = 0.2291). The detailed demographic
ata of the 20 non-responders and 45 responders is shown in Sup-
lementary Table 1. Since no peripheral blood mononuclear cells
PBMC) were available from the non-responders and responders, 29 (2014) 5316–5322 5317
healthy adults who  had physical examination in Peking University
Third Hospital without evidence of prior HBV infection were also
enrolled for further experiments. This study was  approved by the
Ethics Committee of the Peking University Health Science Center
and all subjects provided signed informed consent.
2.2. SNP selection and detection
Six TfH associated molecules CXCR5, ICOS, CXCL13, IL-21, BCL6
and CD40L were selected for SNP analysis. Altogether 24 SNPs
within these genes were chosen for the analysis (Supplemen-
tary Table 2), according to the following 2 criteria: ﬁrst, the
minor allele frequency (MAF) obtained from NCBI SNP database
(http://www.ncbi.nlm.nih.gov/SNP/) or the SNP browser software
4.0 (Applied Biosystems) should be higher than 10% in the eth-
nic Han Chinese population. Second, there should be published
evidence showing that the SNP is associated with some disease.
Genomic DNA extracted as previously described was dissolved in
sterile double distilled water and stored at −20 ◦C [4]. SNP geno-
typing was  undertaken by Bioyong Technology using Sequenom
MassARRAY technology (Bioyong Technology Co., Beijing, China).
2.3. Flow cytometry assays
Peripheral Blood Mononuclear Cells were isolated using
Histopaque-1077 (Sigma, 10771) according to the manufacturer’s
instructions and stored at −80 ◦C. For ﬂow cytometry assays, recov-
ered cells were incubated for 30 min  with a cocktail of antibodies
that included eFluor450 conjugated anti-CD3 mAb  (eBioscience,
48-0038), PE-Cy7 conjugated anti-CD4 mAb  (BD, 557852), APC
conjugated anti-CD19 mAb  (BD, 555415) and PE conjugated anti-
CXCR5 mAb  (eBioscience, 12-9185). Following incubation the cells
were washed with PBS and ﬁxed with 2% paraformaldehyde. Sam-
ples were detected using a BD LSRIIFortessa ﬂow cytometer and
analyzed using FlowJo software.
2.4. Construction of vectors
To construct the miR-558 expression plasmid, a precursor of
the miR-558 sequence ampliﬁed from HepG2 genomic DNA was
cloned into the pRNA-U6.1/Neo-siFluc vector. The 3′-UTR region
of CXCR5 including the rs3922 locus was  ampliﬁed and inserted
downstream of the luciferase reporter gene in pGL3-Control Vector.
The luciferase reporter plasmid carrying an “A” allele in rs3922 was
marked as pGL3-3922A-luc, while the pGL3-3922G-luc contains
the SNP “G”.
2.5. Dual-luciferase reporter assays
HEK 293T cells were seeded into 12-well plates. Twenty-four
hours later, the cells were co-transfected with 1.5 g of miR-558
expression plasmid or U6 control vector and 50 ng pGL3-3922
luciferase vectors. The pRL-TK (25 ng) plasmid was also transfected
as a transfection efﬁciency control. The luciferase activity in each
well was  quantiﬁed 24 h after transfection using a dual luciferase
reporter kit (Promega, Madison, WI,  USA) according to the manu-
facturer’s instructions. In an additional experiment only luciferase
vector (pGL3-3922A-luc or pGL3-3922G-luc) and pRL-TK plasmid
were co-transfected, without the miR-558 expression plasmid or
U6 control vectors. The majority of most experimental conditions
were the same in this case except the quantity of pGL3-3922 vector
added was 100 ng per well.
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Table 1
Association of TfH gene SNPs with non-responsiveness to the HBV vaccine (a P-value < 0.05 is shown in bold and italics).
Gene SNP Genotype and allelotype Non-responders (%) Responders (%) OR (95% CI) P Value
CXCR5 rs3922 AA 5 (25) 23 (56.1) 0.26 (0.08–0.85) 0.063
GG  3 (15) 4 (9.76) 1.63 (0.33–8.11)
AG  12 (60) 14 (34.15) 3.12 (1.02–9.48)
A  allele 22 (55) 60 (73.17) 0.45 (0.20–0.99) 0.045
G  allele 18 (45) 22 (26.83) 2.23 (1.01–4.92)
CXCR5 rs676925 GG 2(10) 1(2.27) 4.78 (0.41–56.07) 0.100
CC  11(55) 34(77.27) 0.36 (0.12–1.11)
CG  7(35) 9(20.45) 2.09 (0.65–6.78)
G  allele 11(27.5) 11(12.5) 2.66 (1.04–6.79) 0.037
C  allele 29(72.5) 77(87.5) 0.38 (0.15–0.96)
CXCR5 rs497916 TT 3 (15) 2 (4.55) 3.71 (0.57–24.18) 0.023
CC  7 (35) 30 (68.18) 0.25 (0.08–0.77)
CT  10 (50) 12 (27.27) 2.67 (0.89–8.01)
T  allele 16 (40) 16 (18.18) 3.00 (1.30–6.90) 0.008
C  allele 24 (60) 72 (81.82) 0.33 (0.14–0.77)
CXCL13 rs355687 TT 10 (52.6) 18 (40.91) 1.60 (0.54–4.74) 0.038
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.6. Statistical analysis
For each SNP, the association between response statuses to HBV
accine and various genotypes or allelotypes was estimated by the
hi-square test using SAS version 9.1.3 (SAS Institute, Inc., Cary, NC,
SA). The Hardy–Weinberg equilibrium (H–W equilibrium) was
alculated based on the control group using Haploview version
.2 software [23]. Linkage disequilibrium (LD) analysis and haplo-
ype construction were carried out with the same software. Speciﬁc
arameters were set as previously published [4]. P-values, odds
atios (OR), and 95% conﬁdence intervals (95% CIs) were obtained
or correlation analysis. A P-value < 0.05 was taken to be statistically
igniﬁcant.
. Results
.1. Associations between TfH gene SNPs and non-responsiveness
o HBV vaccination
A total of 24 SNPs from TfH associated molecules were analyzed
n the 20 non-responders and 45 responders. The genotype and
llele frequencies of all the SNPs in the study and control groups
re listed in Supplementary Table 3. The H–W equilibrium was
valuated in the normal response group and two SNPs (rs3092945,
s715762) in CD40L were excluded from the analysis due to dise-
uilibrium (P < 0.001).
Of the remaining 22 SNPs, four (rs3922, rs676925, rs497916
nd rs355687) showed signiﬁcant associations with the immune
esponse triggered by HBV vaccination (P < 0.05, Table 1). Three
f these were located in the CXCR5 gene: rs3922 (in 3′-UTR),
s676925 (in 3′-UTR) and rs497916 (in intron), while the fourth
ne rs355687 was located in the intron of CXCL13. As collected
y the international HapMap project, the distributions of these 4
NPs in different populations were summarized in the Supplemen-
ary Table 4. What’s worth mentioning, the genotype and allele
requencies in our responder cohort are almost the same as that
mong the Han Chinese in Beijing, China (CHB), as well as the Chi-
ese in Metropolitan Denver, Colorado (CHD) from the HapMap
roject (http://hapmap.ncbi.nlm.nih.gov/). As shown in Table 1,
he ‘G’ allele frequency of rs3922 was signiﬁcantly higher in non-
esponders than those normally responded to HBV vaccination
45% vs. 26.83%, P = 0.045). Consequently carriers of the ‘G’ allele
t rs3922 site had an increased risk of failing to respond to HBV24 (54.55) 0.30 (0.09–0.97)
60 (68.18) 0.90 (0.40–2.01) 0.793
28 (31.82) 1.11 (0.50–2.50)
vaccination than those carrying the ‘A’ allele (OR = 2.23, 95% CI
1.01–4.92). Similarly, the minor allele ‘G’ in rs676925 increased the
risk of non-response to vaccination (OR = 2.66, 95% CI 1.04–6.79,
P = 0.037). In the case of rs497916, both the allelotype and geno-
type were related with HBV vaccine efﬁcacy (allelotype: P = 0.008,
genotype: P = 0.023). The ‘C’ allele in rs497916 protected from non-
response (OR = 0.33, 95% CI 0.14–0.77) and the genotypes ‘TT’ and
‘CT’ increased the possibility of non-response to vaccination (‘TT’:
OR = 3.71, 95% CI 0.57–24.18, ‘CT’: OR = 2.67, 95% CI 0.89–8.01).
Finally, the ‘TC’ genotype in rs355687 appears more frequently in
the group deﬁned as HBV responders (P = 0.038, OR = 0.30, 95% CI
0.09–0.97).
3.2. Association of SNP haplotypes and non-responsiveness to
HBV vaccination
Using the Haploview software, three possible blocks were con-
structed (Fig. 1). Strong linkage disequilibrium was found in two
haplotypes in block one which was  made up of rs497916, rs3922
and rs676925 within CXCR5. Compared to HBV vaccination respon-
ders, the ‘CAC’ haplotype had a signiﬁcantly lower frequency in
non-responders (Responders vs. non-responders: 0.735 vs. 0.513,
P = 0.013). The frequency of the ‘TGG’ haplotype was  0.266 in the
study group and only 0.111 in the control group (P = 0.025). That
is, an individual who has a ‘TGG’ haplotype containing the three
risk alleles of rs497916, rs3922 and rs676925 is signiﬁcantly more
likely to have non-responsiveness to HBV vaccination.
3.3. The rs3922 affects CXCR5 expression on circulating CD4+T
and CD19+ B cells.
Changes in the SNP located in the 3′-UTR may  cause a ﬂuc-
tuation in gene expression. To understand whether the 2 chosen
SNPs (rs3922, rs676925) that fall in the 3′-UTR of CXCR5 affected
gene’s expression levels, ﬂow cytometry assays were performed to
detect CXCR5+ populations in PBMCs from 29 healthy individuals.
Based on their genotypes in rs3922 or rs676925, this cohort was
divided into 3 groups. The percentage of CXCR5 positive cells and
the mean ﬂuorescence intensity (MFI) of CXCR5 in CD3+CD4+ T cell
and CD3−CD19+ B cell populations were compared amongst these
3 groups. The gating strategy employed is deﬁned in Fig. 2A. As
summarized in Fig. 2B, in both CD4+CD3+ T cell and CD19+CD3− B
cell populations, the percentage and MFI  values for CXCR5+ cells








































mig. 1. Three possible blocks using the data of 24 SNPs from the HBV vaccination
arked in the crossing areas and the value 100 was omitted.
n the rs3922 “GG” genotype group were signiﬁcantly higher than
hose seen for the “AG” group (P < 0.05). Merging the data from
oth the “AA” group and “AG” group, still resulted in a statisti-
al difference (P < 0.05), implying that the percentage of CXCR5+
ells is higher in the “GG” group than in the “non-GG” group. The
ame conclusion was true for the MFI  value of CXCR5. However,
o signiﬁcant difference was observed when similar analysis was
arried out on rs676925 (Supplementary Fig. 2). These results sug-
ested that rs3922 might be involved in non-responsiveness to HBV
accination through affecting the level of CXCR5 expression.
.4. Experiments in vitro conﬁrm the inﬂuence of rs3922 on
XCR5 gene expression.
Targetscan (http://www.targetscan.org/) prediction suggested
hat the rs3922 SNP is located in a potential microRNA binding
ite for miR-558 when the A allele is present, but not the G allele.
o investigate whether allelic change in rs3922 can result in miR-
58 regulated differences in the expression of CXCR5, luciferase
ectors pGL3-3922A-luc and pGL3-3922G-luc differing only in the
llelic version of the potential miRNA binding site were con-
tructed (Fig. 3A). These luciferase vectors were independently
o-transfected into HEK293T cells together with either miR-558
xpressing or U6 control plasmids. Strikingly, cells co-transfected
ith pGL3-3922A-luc produced signiﬁcantly lower luciferase activ-
ty than those co-transfected with pGL3-3922G-luc irrespective
f whether the co-transfection was with the U6 control plas-
id  or that expressing miR-558 (Fig. 3B). Similarly, when only
he luciferase reporter vector alone was transfected into cells,
he lowest relative level of luciferase activity was  recorded from
GL3-3922A-luc and the difference between the level of luciferase
xpressed by the pGL3-3922A-luc and that by the pGL3-3922G-luc
as statistically signiﬁcant (Fig. 3C).
. Discussion
The standard HBV vaccination regime provides protection from
BV infection in most vaccinees, leaving only 5–10% of recipients
eﬁned as non-responders. A variety of factors, including gene
olymorphisms, have been found to cause inadequate antibody
roduction and hence limit the efﬁcacy of the HBV vaccine [4,24].
ollowing the recognition that TfH cells play an important role in
ntibody responses, this study focused on the genes encoding 6
olecules associated with TfH cells (CXCR5, CXCL13, ICOS, CD40L,nsiveness and non-responsiveness groups. The paired-wise D′ value (100×) was
IL-21 and BCL6), to evaluate possible associations of polymor-
phisms in them with immune responses made to HBV vaccination.
This SNP based association analysis clearly showed that
polymorphisms in CXCR5 and CXCL13 were associated with non-
responsiveness to the HBV vaccine. CXCR5 and CXCL13 appear to
be inter-related not only in terms of anatomical location, but also
in terms of the functioning of TfH cells [25]. These two  molecules
are expressed both by TfH cells and B cells [26,27]. The encounter
between a CD4+ helper T cell and a cognate B cell is essential for TfH
cells to offer help in the production of antibody by B cells and it has
been suggested that proper interplay between CXCR5 and CXCL13
is the impetus for TfH cells and B cells to migrate to B cell follicles
[28]. Consequently, changes in the expression level of these two
molecules may  affect the interaction between TfH and B cells and
subsequently the humoral response to vaccination. Annamalai and
Selvaraj have reported in birds that following receipt of a coccidial
vaccine, the mRNA level of CXCR5 in some speciﬁc organs increased
substantially [29]. Also Guo et al. have shown that fusion of a vac-
cine antigen directly to CXCL13 could enhance DNA vaccine potency
[30]. Thus, the linkage of CXCR5, CXCL13 polymorphisms to HBV
vaccine efﬁcacy is consistent with these other studies indicating
that TfH cells played a critical role in antibody production.
The majority of previous studies have suggested that circu-
lating CXCR5+CD4+ T cells have the essential features similar to
the TfH cells from lymphoid organs [31,32]. So we compared the
CXCR5 positive populations in CD3+CD4+ T cells or CD3−CD19+
B cells in peripheral blood from different genotype populations.
In an attempt to demonstrate an association between the SNPs
in the 3′-UTR (rs3922 and rs676925) and gene expression level,
29 healthy volunteers were recruited and genotyped. This was
necessary because of the paucity of RNA or PBMCs from the respon-
ders and non-responders to HBV vaccination making up the study
cohort. Individuals with rs3922 “GG” genotype had a higher CXCR5
expression level in the blood than “non-GG” groups. This observa-
tion was concordant with our luciferase assays and hence the data
suggested that “G” allele may  correlate with a relative high gene
expression. In the current study, a role for miR-558 was  excluded
and the detailed mechanism by which the “G” allele favors CXCR5
gene expression remains unknown.
It appears counter-intuitive that the “G” allele, which is asso-
ciated with the non-responder phenotype, should correspond to a
higher expression of CXCR5. However, it remains unclear whether
higher CXCR5 expression on TfH cells will enhance their B cell help
function. In fact, Bentebibel et al. have reported that, in human
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Fig. 2. The characteristics of CXCR5 expression in circulating total CD4+T cells and B cells were compared among different genotypes of rs3922 in 29 healthy controls. (A)
Deﬁning the gating strategy. CXCR5+ populations were derived from CD4+CD3+ or CD19+CD3− lymphocytes. (B) Whether in the CD4+CD3+ T cells or in the CD19+CD3− B
cells,  the percentage and MFI of CXCR5+ population were signiﬁcantly higher in the group with “GG” genotype in rs3922 than in the “AG” group or in the “non-GG” group
(P  < 0.05).
Z. Duan et al. / Vaccine 32 (2014) 5316–5322 5321
Fig. 3. Dual-luciferase report assays to identify the effects of rs3922 on gene expression. (A) miR-558 was predicted to be the target of 3′-UTR sequence containing rs3922. (B)
All  the luciferase vectors produce a lower activity in the group co-transfected with miR-558 than U6 control. What’s more, the relative luciferase activity gradually decreased




































[ransfected with U6 or miR-558. (C) The relative luciferase activity was  lowest in p
roup was  statistically signiﬁcant.
onsils, the CD4+ subset (CXCR5loCD4+) expressing low levels of
XCR5 secreted more IL-21 and IL-10 than the high expression sub-
et (CXCR5hi). They also appeared to provide more efﬁcient help for
he differentiation of naive B cells into Ig-producing cells outside
he germinal center [33].
Overall, this study supports the idea that polymorphisms in
XCR5 and CXCL13, two of TfH associated genes, are closely related
o the non-responsiveness to HBV vaccination. The restricted num-
er of non-responsive individuals in our cohort population and
he consequent limitation in the availability of blood samples pre-
luded further investigation of how the polymorphisms in CXCR5
nd CXCL13 might affect the functioning of these genes. Therefore,
ow the expression levels of these genes can affect the efﬁcacy
f HBV vaccination is still a puzzle. However, achieving a better
nderstanding of the functions of CXCR5 and CXCL13, particularly
n response to HBV vaccination, may  provide clues that can facilitate
ptimization of HBV vaccines.
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